Embecta Corp. investors who bought securities between November 25, 2025 and May 4, 2026 have until August 17, 2026 to seek appointment as lead plaintiff in a proposed securities class action, according to a reminder from Glancy Prongay Wolke & Rotter LLP. The complaint alleges the company made materially false or misleading statements and omitted adverse facts about its business, including that its guidance was misleading and unattainable, that weakness in the United States pen needle market was likely to hurt revenue guidance and second-quarter 2026 results, and that positive statements about the business lacked a reasonable basis. The case follows Embecta’s May 5, 2026 release of second-quarter fiscal 2026 results showing revenue fell more than 14%, largely because of weak pen needle sales, alongside lower guidance for the rest of fiscal 2026. Shares dropped $5.35, or 57.8%, to close at $3.90 that day. Investors do not need to take action now to remain members of the putative class, though they may seek lead plaintiff status or choose their own counsel.